Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | HTRA1 | Q92743 | 5/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738003 | 0.87 | CMA1 (0.52) | ELANECTSG | |
| SCHEMBL6738980 | 0.81 | ELANE (0.41) | ELANECTSGHTRA1 | |
| SCHEMBL6741140 | 0.81 | ELANE (0.61) | ELANECTSG | |
| SCHEMBL13815175 | 0.80 | AGTR2 (0.40) | ELANEAGTR2BDKRB2 | |
| SCHEMBL6742331 | 0.78 | DPP4 (0.45) | ELANECTSGHTRA1 | |
| SCHEMBL19899291 | 0.76 | HTRA1 (0.55) | HTRA1 | |
| SCHEMBL19899288 | 0.76 | HTRA1 (0.55) | HTRA1 | |
| SCHEMBL19899281 | 0.74 | HTRA1 (0.64) | HTRA1 | |
| SCHEMBL19899280 | 0.74 | HTRA1 (0.64) | HTRA1 | |
| SCHEMBL19899298 | 0.74 | HTRA1 (0.46) | HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | ELANE 1/4885CTSG 91/4885HTRA1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.